Copanlisib

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Copanlisib
Copanlisib.svg
Clinical data
Trade names Aliqopa (US)
Synonyms BAY 80-6946
AHFS/Drugs.com Aliqopa
MedlinePlus a617044
License data
Routes of
administration
intravenous infusion only
Drug class PI3-Kinase inhibitor
ATC code
  • none
Legal status
Legal status
Pharmacokinetic data
Protein binding 84.2%[1]
Metabolism CYP3A4/5 (~90%), CYP1A1 (~10%)[1]
Elimination half-life 39.1 hours (range: 14.6 to 82.4)[1]
Excretion Feces (64%), Urine (22%); 14% were not recovered[1]
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
Formula C23H28N8O4
Molar mass 480.53 g·mol−1
3D model (JSmol)

Copanlisib (trade name Aliqopa /ˌælɪˈkpə/ AL-ih-KOH-pah;[1] codenamed BAY 80-6946) is a drug which is approved by US FDA for the treatment of adult patients experiencing relapsed follicular lymphoma who have received at least two prior systemic therapies[2].

Copanlisib has been shown to have an effect against survival and spread of cancerous B-cells.

Efficacy resulting in the approval of copanlisib was based on the subgroup of 104 patients with follicular lymphoma from a Phase 2 clinical trial.[3] Of these, 59 percent had a complete or partial shrinkage of their tumors that lasted about 12 months. To assess the safety of the drug, data from 168 adults with follicular lymphoma and other hematologic malignancies treated with copanlisib were evaluated.[4]

Copanlisib is administered as intravenous infusion on a weekly but intermittent schedule (three weeks on and one week off).

Copanlisib is currently approved only in the United States.

Adverse effects[edit]

Data for safety and efficacy of copanlisib are described in a consumer-friendly way in the FDA Drug Trial Snapshot.[4] Copanlisib can cause serious side effects including infections, hyperglycemia, hypertension, pneumonitis, neutropenia and skin rashes. The most common side effects of copanlisib are hyperglycemia, diarrhea, decreased general strength and energy, hypertension, leukopenia, neutropenia, nausea, lower respiratory tract infections and thrombocytopenia. Copanlisib can cause harm to unborn babies. Patients with reproductive potential are thus advised to use effective contraception. Lactating patients are advised to not breastfeed.

Mechanism of action[edit]

Copanlisib is an inhibitor of phosphatidylinositol-3-kinase (PI3K) with inhibitory activity predominantly against PI3K-α and PI3K-δ isoforms expressed in malignant B-cells. It has been shown to induce tumor cell death by apoptosis and inhibition of proliferation of primary malignant B cell lines.[1]

Regulatory history[edit]

Follicular lymphoma[edit]

For follicular lymphoma, the FDA awarded copanlisib orphan drug status in February 2015 and fast track designation in February 2016.[5]. The NDA for follicular lymphoma was granted priority review in May 2017.[6]

In September 2017, it received accelerated approval (FDA regulation 21 CFR Part 314 subpart H) for the treatment of adult patients experiencing relapsed follicular lymphoma who have received at least two prior systemic therapies. Further clinical trials are to be performed as a post-marketing requirement to verify the clinical benefit.[7]

Other[edit]

Copanlisib was granted orphan drug status for the treatment of splenic, nodal and extranodal subtypes of marginal zone lymphoma.[6]

Clinical trials[edit]

Phase II clinical trials are in progress for treatment of endometrial cancer,[8] diffuse large B-cell lymphoma,[9] cholangiocarcinoma,[10] and non-Hodgkin lymphoma.[3] Copanlisib in combination with R-CHOP or R-B (rituximab and bendamustine) is in a phase III trial for relapsed indolent non-Hodgkin lymphoma (NHL).[11] Two separate phase III trials are investigating the use of copanlisib in combination with rituximab for indolent NHL[12] and the other using copanlisib alone in cases of rituximab-refractory indolent NHL.[13]

In a preclinical study, copanlisib was effective in inhibiting HER2+ breast cancer cells with acquired resistance to the HER2-inhibitors trastuzumab and/or lapatinib. This effect was increased when copanlisib was administered along with the aforementioned HER2-inhibitors.[14] Consequently, treatments of copanlisib with trastuzumab are being clinically trialled in HER2-positive breast cancer patients.[15]

References[edit]

  1. ^ a b c d e f "FDA Prescribing information for Aliqopa" (PDF). 
  2. ^ Food and Drug Administration. "FDA News Alert: FDA approves new treatment for adults with relapsed follicular lymphoma". www.fda.gov. 
  3. ^ a b "Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas - Full Text View - ClinicalTrials.gov". 
  4. ^ a b Food and Drug Administration. "Drug Trials Snapshots ALIQOPA". www.fda.gov. 
  5. ^ Food and Drug Administration. "NDA 209936, Multisciplinary Review document, chapter 3" (PDF). www.fda.gov. 
  6. ^ a b Bayer AG (17 May 2017). "Bayer News Release" (PDF). www.bayer.com. 
  7. ^ Food and Drug Administration. "NDA 209936, Approval Letter" (PDF). www.fda.gov. 
  8. ^ "Copanlisib in Treating Patients With Persistent or Recurrent Endometrial Cancer - Full Text View - ClinicalTrials.gov". 
  9. ^ "Phase II Copanlisib in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) - Full Text View - ClinicalTrials.gov". 
  10. ^ "Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma - Full Text View - ClinicalTrials.gov". 
  11. ^ "Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL) - Full Text View - ClinicalTrials.gov". 
  12. ^ "Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL) - Full Text View - ClinicalTrials.gov". 
  13. ^ "Phase III Copanlisib in Rituximab-refractory iNHL - Full Text View - ClinicalTrials.gov". 
  14. ^ Elster, N.; Cremona, M.; Morgan, C.; Toomey, S.; Carr, A.; O’Grady, A.; Hennessy, B. T.; Eustace, A. J. (2015-01-01). "A preclinical evaluation of the PI3K alpha/delta dominant inhibitor BAY 80-6946 in HER2-positive breast cancer models with acquired resistance to the HER2-targeted therapies trastuzumab and lapatinib". Breast Cancer Research and Treatment. 149 (2): 373–383. doi:10.1007/s10549-014-3239-5. ISSN 0167-6806. 
  15. ^ "Phase Ib/II Trial of coPANlisib in Combination With Trastuzumab in HER2-positive Breast Cancer. (Panther Study) - Full Text View - ClinicalTrials.gov". Retrieved 2017-11-24.